BRPI0517083A - uso de 4-(4-metilpiperazin-1-ilmetil)-n-{4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil}-benzamida para inibir o receptor c-fms de tirosina quinase - Google Patents

uso de 4-(4-metilpiperazin-1-ilmetil)-n-{4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil}-benzamida para inibir o receptor c-fms de tirosina quinase

Info

Publication number
BRPI0517083A
BRPI0517083A BRPI0517083-4A BRPI0517083A BRPI0517083A BR PI0517083 A BRPI0517083 A BR PI0517083A BR PI0517083 A BRPI0517083 A BR PI0517083A BR PI0517083 A BRPI0517083 A BR PI0517083A
Authority
BR
Brazil
Prior art keywords
methylpiperazin
ylamino
benzamide
pyrimidin
ylmethyl
Prior art date
Application number
BRPI0517083-4A
Other languages
English (en)
Inventor
Andrea Louis Dewar
Timothy Peter Hughes
Alan Bruce Lyons
Original Assignee
Medvet Science Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medvet Science Pty Ltd filed Critical Medvet Science Pty Ltd
Publication of BRPI0517083A publication Critical patent/BRPI0517083A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

USO DE 4-(4-METILPIPERAZIN-1 -ILMETIL)-N-¢4-METIL-3-(4-PIRIDIN-3-IL)PIRIM IDIN-2-ILAMINO)FENIL!-BENZAMIDA PARA INIBIR O RECEPTOR C-FMS DE TIROSINA QUINASE. A presente invenção refere-se ao uso de 4-(4-metilpiperazin-1- ilmetil)-N-¢4-metil-3-(4-piridin-3-iI)pirimid in-2-ilamino)fenil!-benzamida (também conhecida como imatinib, gleevec, glivec, cgp57148b ou 8T1571), ou seu sal farmaceuticamente aceitável, para a fabricação de um medicamento para o tratamento de doenças associadas a c-fms, incluindo: coriocarcinoma, histiocitose maligna, carcinoma embrionário, carcinoma endometrial, tumores microgliais de cérebro, sarcoidose, envolvimento de células microgliais na doença de Creutzfeld-Jacob normal e variante ou esclerose lateral amiotrófica.
BRPI0517083-4A 2004-10-18 2005-10-17 uso de 4-(4-metilpiperazin-1-ilmetil)-n-{4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil}-benzamida para inibir o receptor c-fms de tirosina quinase BRPI0517083A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61974404P 2004-10-18 2004-10-18
PCT/AU2005/001602 WO2006042362A1 (en) 2004-10-18 2005-10-17 Use of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fms

Publications (1)

Publication Number Publication Date
BRPI0517083A true BRPI0517083A (pt) 2008-09-30

Family

ID=36202610

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517083-4A BRPI0517083A (pt) 2004-10-18 2005-10-17 uso de 4-(4-metilpiperazin-1-ilmetil)-n-{4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil}-benzamida para inibir o receptor c-fms de tirosina quinase

Country Status (19)

Country Link
US (1) US20080255139A1 (pt)
EP (1) EP1804800B1 (pt)
JP (1) JP2008516898A (pt)
KR (1) KR20070083705A (pt)
CN (1) CN101035535A (pt)
AT (1) ATE492277T1 (pt)
AU (1) AU2005297321A1 (pt)
BR (1) BRPI0517083A (pt)
CA (1) CA2580976A1 (pt)
DE (1) DE602005025514D1 (pt)
IL (1) IL182419A0 (pt)
MA (1) MA28946B1 (pt)
MX (1) MX2007004660A (pt)
NO (1) NO20072501L (pt)
NZ (1) NZ554009A (pt)
RU (1) RU2007118420A (pt)
TN (1) TNSN07141A1 (pt)
WO (1) WO2006042362A1 (pt)
ZA (1) ZA200702316B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011502266A (ja) * 2007-10-31 2011-01-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｆｍｓ治療に対する応答を評価するバイオマーカー
WO2016114322A1 (ja) * 2015-01-13 2016-07-21 国立大学法人京都大学 筋萎縮性側索硬化症の予防及び／又は治療剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837237A (en) * 1985-07-09 1989-06-06 Fred Hutchinson Cancer Research Center Therapy using glucosidase processing inhibitors
ATE331519T1 (de) * 2001-05-16 2006-07-15 Gpc Biotech Ag Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten
AU2003295320A1 (en) * 2002-06-26 2004-04-08 The Ohio State University Research Foundation The method for reducing inflammation using sti-571 or its salt

Also Published As

Publication number Publication date
US20080255139A1 (en) 2008-10-16
RU2007118420A (ru) 2008-11-27
CA2580976A1 (en) 2006-04-27
MX2007004660A (es) 2007-10-17
KR20070083705A (ko) 2007-08-24
NZ554009A (en) 2010-09-30
TNSN07141A1 (en) 2008-11-21
AU2005297321A1 (en) 2006-04-27
NO20072501L (no) 2007-05-15
WO2006042362A1 (en) 2006-04-27
IL182419A0 (en) 2007-09-20
EP1804800A4 (en) 2008-03-19
DE602005025514D1 (de) 2011-02-03
MA28946B1 (fr) 2007-10-01
ATE492277T1 (de) 2011-01-15
CN101035535A (zh) 2007-09-12
EP1804800B1 (en) 2010-12-22
JP2008516898A (ja) 2008-05-22
ZA200702316B (en) 2008-09-25
EP1804800A1 (en) 2007-07-11

Similar Documents

Publication Publication Date Title
PT1332137E (pt) Tratamento de tumores estromais gastrintestinais
IL177005A0 (en) Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
NO20075624L (no) Nye histamin H3-reseptorligander og deres terapeutiske anvendelser
MY146403A (en) F, g, h, i and k crystal forms of imatinib mesylate
PE20121476A1 (es) Composicion para el tratamiento de trastornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r
BR0312873A (pt) 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil] benzamida para tratamento de doenças associadas com ret cinase mutante
NZ590177A (en) Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
HRP20100265T1 (hr) Smjesa od pirimidilaminobenzamid spojeva i imatiniba za liječenje ili prevenciju proliferativnih bolesti
JP2008542390A5 (pt)
BRPI0517083A (pt) uso de 4-(4-metilpiperazin-1-ilmetil)-n-{4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil}-benzamida para inibir o receptor c-fms de tirosina quinase
IL171927A0 (en) Use of tyrosine kinase inhibitor to treat diabetes
PE20141337A1 (es) Formulacion de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida
IL162983A (en) Use of imatinib for the manufacture of pharmaceutical compositions for the treatment of rheumatoid arthritis
AU2003216621A8 (en) Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer
RU2020127993A (ru) Терапевтическое средство для лечения гепатоцеллюлярной карциномы
TH114424B (th) ยาสำเร็จรูปชนิดของแข็ง

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2211 DE 21/05/2013.